Radiography Acquisition Software ‘VXvue’ Receives FDA 510(k) Clearance
2025-11-12

Vieworks, a global provider of medical and
industrial imaging solutions, said its digital image acquisition and processing
software ‘VXvue’ has received U.S. FDA 510(k) clearance. The clearance enables
the company to offer a fully integrated medical imaging solutiom—combining
detectors and proprietary software—in the North American market.
This marks Vieworks’ first FDA
clearance for software featuring AI-driven image enhancement. The company met
strengthened regulatory requirements, demonstrating substantial equivalence,
quality management, and post-market surveillance procedure.
VXvue provides acquisition, transmission
and image processing tailored to Vieworks’ X-ray detectors. Its ‘PureImpact™’
algorithm sharpens clinical images and enhances visualization of soft tissue
and bone. The software also includes presets for humans, veterinary, and vehicle-based
workflows.
Recent updates incorporate multiple
AI-based tools, including ‘Bone-X AI’ for improved soft-tissue visibility in
chest radiographs and ‘Noise-X AI’, a deep-learning based noise-reduction
algorithm.
Vieworks has expanded its regulatory
footprint across the U.S. and Europe. The company gained FDA clearance for
three X-ray detectors over the past year, and its VISQUE DPS digital pathology
scanner recently earned CE-IVDR certification. The company plans to highlight
VXvue and its new detector lineup at RSNA 2025 later this month.
“FDA clearance confirms that Vieworks is
not only strong in hardware but also advancing in software innovation,” a
company spokesperson said. “We will continue developing solutions that support
low-dose imaging, clinical workflow efficiency and evolving global regulatory
standards.”
- Previous
- List

- Next
